Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome
| Autor: | Beatrice Files, J. Michael Grindel, Lori Luchtman-Jones, Lee Hilliard, Miguel R. Abboud, Thomas D. Coates, Paul Swerdlow, Frans A. Kuypers, Lennette Benjamin, Samir K. Ballas, Slawomir Wojtowicz-Praga |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Lung Diseases Male medicine.medical_specialty Adolescent Clinical Biochemistry Cell Embolism Fat Disease Anemia Sickle Cell Gastroenterology Group II Phospholipases A2 Secretory Phospholipase A2 Phospholipases A Predictive Value of Tests Internal medicine medicine Humans In patient Child Genetics (clinical) business.industry Biochemistry (medical) Hematology Syndrome medicine.disease Sickle cell anemia Acute chest syndrome Phospholipases A2 medicine.anatomical_structure Multicenter study Child Preschool Acute Disease Female business Pulmonary Embolism Biomarkers Follow-Up Studies |
| Zdroj: | Hemoglobin. 30(2) |
| ISSN: | 0363-0269 |
| Popis: | In a multicenter study (eight centers), we determined secretory phospholipase A(2) (sPLA(2)) levels in patients with sickle cell disease and acute chest syndrome (ACS). The diagnosis of ACS was made according to established criteria. The sPLA2 levels were determined in blood samples collected at baseline (time of diagnosis) and serially thereafter up to day 22-35 follow-up visits. Thirty-four of 43 (80%) patients with ACS had enzyme levelsor =1.00 AU at baseline. The enzyme levels decreased significantly on Days 2 through Days 25-35 after baseline. Nine of 43 (20%) patients had baseline sPLA2 values of1.00 AU with six of them never exceeding 1.00 AU at any point in time during follow-up. The data indicate that the reliability of sPLA(2( for predicting the development of ACS is not perfect (100%) as was previously reported but occurs in about 80% of the patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|